Review





Similar Products

ewing sarcoma cell lines  (ATCC)
95
ATCC ewing sarcoma cell lines
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Ewing Sarcoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/pmc13231080-570-1-23?v=ATCC
Average 95 stars, based on 1 article reviews
ewing sarcoma cell lines - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier
archer fusionplex sarcoma v2 panel  (Integrated DNA Technologies)
99
Integrated DNA Technologies archer fusionplex sarcoma v2 panel
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Archer Fusionplex Sarcoma V2 Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/custom%40fusionplex-sarcoma-v2-panel%4042391872?v=Integrated+DNA+Technologies
Average 99 stars, based on 1 article reviews
archer fusionplex sarcoma v2 panel - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
uterine sarcoma messa  (ATCC)
96
ATCC uterine sarcoma messa
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Uterine Sarcoma Messa, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/pm42284392-241-12-28?v=ATCC
Average 96 stars, based on 1 article reviews
uterine sarcoma messa - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
sarcoma  (Sanofi)
86
Sanofi sarcoma
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Sarcoma, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/pmc13268934-27-11-4?v=Sanofi
Average 86 stars, based on 1 article reviews
sarcoma - by Bioz Stars, 2026-08
86/100 stars
  Buy from Supplier
u2os human bone sarcoma cell line  (ATCC)
99
ATCC u2os human bone sarcoma cell line
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
U2os Human Bone Sarcoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/pm42141265-278-7-15?v=ATCC
Average 99 stars, based on 1 article reviews
u2os human bone sarcoma cell line - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
archer variantplex core solid tumor panel  (Integrated DNA Technologies)
99
Integrated DNA Technologies archer variantplex core solid tumor panel
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Archer Variantplex Core Solid Tumor Panel, supplied by Integrated DNA Technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/custom%40variantplex-core-solid-tumor-panel%4042101690?v=Integrated+DNA+Technologies
Average 99 stars, based on 1 article reviews
archer variantplex core solid tumor panel - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier
ewing sarcoma ews cell line a673  (ATCC)
96
ATCC ewing sarcoma ews cell line a673
Three EWSR1::FLI1 fusion protein isoforms were expressed in the <t>Ewing</t> <t>sarcoma</t> <t>cell</t> <t>lines</t> with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.
Ewing Sarcoma Ews Cell Line A673, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sarcomas/pm42071199-66-1-11?v=ATCC
Average 96 stars, based on 1 article reviews
ewing sarcoma ews cell line a673 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


Three EWSR1::FLI1 fusion protein isoforms were expressed in the Ewing sarcoma cell lines with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.

Journal: iScience

Article Title: FusionTarget: Computational framework for drug repurposing against modeled fusion protein structures from genomic breakpoints

doi: 10.1016/j.isci.2026.116076

Figure Lengend Snippet: Three EWSR1::FLI1 fusion protein isoforms were expressed in the Ewing sarcoma cell lines with the same breakpoints, and their MDS analyses were performed with seven selected drugs (A) Normalized binding affinity scores of the seven chosen drugs. A/D depicts the normalized binding affinity fold change between the fusion protein and wild-type protein. (B) Cancer cell line expressed three EWSR1::FLI1 fusion protein isoforms. (C) Molecular dynamics simulation results between three EWSR1::FLI1 fusion protein isoforms and seven chosen drugs. (D) Small molecule-fusion protein complex in 3D.

Article Snippet: The Ewing sarcoma cell lines (RD-ES and SK-ES-1) containing the EWS-FLI1 fusion protein employed in this project so far were purchased from the American Tissue Culture Collection (ATCC).

Techniques: Binding Assay

Ewing sarcoma cell line sensitivity validation of the predicted EWSR1::FLI1 inhibitors (A) Previous studies of seven drugs in sarcoma. (B) IC 50 values for each cell line/drug combination. (C) Percent viability graphs depicting the IC 50 for each cell line drug combination at a log 10 [concentration]. Error bars have been removed for clarity. (D) Cell proliferation assay to assess the sensitivity of Ewing sarcoma cells to EWSR1::FLI1-predicted inhibitors over a 96-h time course, compared with rhabdomyosarcoma cells treated at the highest Ewing sarcoma IC 50 concentration. (E) Significant differential binding scores between normalized ones targeting fusion proteins and normalized ones targeting the wild-type FLI1 across six EWSR1::FLI1 fusions. (F) 200 nsec period MDS comparison of trifluridin, valruvicin, and the most studied small molecule TK-216 between EWSR1::FLI1 (587AA) fusion protein and FLI1 WT protein. (G) Top: mRNA level of NROB1 was examined in EWSR1::FLI1 positive and negative fusion cells. Bottom: mRNA level of TGFBR2 was examined in EWSR1::FLI1 positive and negative fusion cells. For all bar graphs, results are shown for statistical analyses done in three replicates; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001.

Journal: iScience

Article Title: FusionTarget: Computational framework for drug repurposing against modeled fusion protein structures from genomic breakpoints

doi: 10.1016/j.isci.2026.116076

Figure Lengend Snippet: Ewing sarcoma cell line sensitivity validation of the predicted EWSR1::FLI1 inhibitors (A) Previous studies of seven drugs in sarcoma. (B) IC 50 values for each cell line/drug combination. (C) Percent viability graphs depicting the IC 50 for each cell line drug combination at a log 10 [concentration]. Error bars have been removed for clarity. (D) Cell proliferation assay to assess the sensitivity of Ewing sarcoma cells to EWSR1::FLI1-predicted inhibitors over a 96-h time course, compared with rhabdomyosarcoma cells treated at the highest Ewing sarcoma IC 50 concentration. (E) Significant differential binding scores between normalized ones targeting fusion proteins and normalized ones targeting the wild-type FLI1 across six EWSR1::FLI1 fusions. (F) 200 nsec period MDS comparison of trifluridin, valruvicin, and the most studied small molecule TK-216 between EWSR1::FLI1 (587AA) fusion protein and FLI1 WT protein. (G) Top: mRNA level of NROB1 was examined in EWSR1::FLI1 positive and negative fusion cells. Bottom: mRNA level of TGFBR2 was examined in EWSR1::FLI1 positive and negative fusion cells. For all bar graphs, results are shown for statistical analyses done in three replicates; ∗, p < 0.05; ∗∗, p < 0.01; and ∗∗∗, p < 0.001.

Article Snippet: The Ewing sarcoma cell lines (RD-ES and SK-ES-1) containing the EWS-FLI1 fusion protein employed in this project so far were purchased from the American Tissue Culture Collection (ATCC).

Techniques: Biomarker Discovery, Concentration Assay, Proliferation Assay, Binding Assay, Comparison